共 82 条
[1]
Boughey JC(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positivie breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JAMA 310 1455-1461
[2]
Suman VJ(2015)Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study J Clin Oncol 33 258-264
[3]
Mittendorf EA(2013)Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA a prospective multicentre cohort study Lancet Oncol 14 609-618
[4]
Boileau JF(2014)Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial Ann Surg 260 608-616
[5]
Poirier B(2014)Pathologic complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172
[6]
Basik M(2011)Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Breast Cancer Res Treat 125 145-156
[7]
Kuehn T(2020)How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery? Ann Surg Oncol 27 4702-4710
[8]
Banenfeind I(2020)Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis Ann Surg Oncol 27 4669-4677
[9]
Fehm T(2011)Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial JAMA 305 569-575
[10]
Boughey JC(2014)Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Lancet Oncol 15 1303-1310